Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CDXC Stock Summary
Top 10 Correlated ETFs
CDXC
In the News
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex.
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #IR--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference. Mr. Fried and Mrs. Gerber will participate in virtual one-on-one meetings throughout the event on Thursday, February 1, 2024. To arrange a meeting with the Chrom.
ChromaDex: Growth At A Reasonable Price
Nutraceuticals and supplements industry is gaining traction due to increasing demand for products that promote well-being. ChromaDex Corporation offers an interesting technology and product, Niagen, which boosts NAD+ levels in the body. ChromaDex's Q3 performance showed substantial sales growth and improvement in gross margin, making it an attractive investment opportunity.
ChromaDex Corporation (CDXC) Q3 2023 Earnings Call Transcript
ChromaDex Corporation (CDXC) Q3 2023 Earnings Call Transcript
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Bioscience--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 8, 2023 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDe.
ChromaDex Corporation (CDXC) Q2 2023 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC ) Q2 2023 Earnings Call Transcript August 9, 2023 4:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - Chief Executive Officer Brianna Gerber - Chief Financial Officer Conference Call Participants Ram Selvaraju - H.C. Wainwright Jeff Van Sinderen - B.
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, August 9, 2023 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended on June 30, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will.
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023 Investor Conference. Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event on Thursday, May 18, 2023. To arrange a meeting with the ChromaDex management team, please contact.
ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates
ChromaDex (CDXC) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.11 per share a year ago.
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Q1Earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex manage.
CDXC Financial details
CDXC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.81 | 0.97 | 1 | 1.05 | 1.11 | |
Net income per share | -0.55 | -0.3 | -0.38 | -0.21 | -0.07 | |
Operating cash flow per share | -0.36 | -0.17 | -0.36 | -0.22 | 0.09 | |
Free cash flow per share | -0.37 | -0.18 | -0.37 | -0.22 | 0.09 | |
Cash per share | 0.33 | 0.27 | 0.42 | 0.29 | 0.36 | |
Book value per share | 0.36 | 0.27 | 0.47 | 0.42 | 0.38 | |
Tangible book value per share | 0.34 | 0.25 | 0.46 | 0.41 | 0.37 | |
Share holders equity per share | 0.36 | 0.27 | 0.47 | 0.42 | 0.38 | |
Interest debt per share | 0.02 | 0.03 | 0.07 | 0.06 | 0.04 | |
Market cap | 245.91M | 293.12M | 251.27M | 115.78M | 107.23M | |
Enterprise value | 228.82M | 278.26M | 227.95M | 99.8M | 83.18M | |
P/E ratio | -7.81 | -15.86 | -9.83 | -8.01 | -21.71 | |
Price to sales ratio | 5.31 | 4.95 | 3.73 | 1.61 | 1.28 | |
POCF ratio | -12.03 | -27.65 | -10.4 | -7.67 | 15.23 | |
PFCF ratio | -11.6 | -27.29 | -10.23 | -7.5 | 15.55 | |
P/B Ratio | 12.03 | 17.85 | 7.92 | 4.04 | 3.77 | |
PTB ratio | 12.03 | 17.85 | 7.92 | 4.04 | 3.77 | |
EV to sales | 4.94 | 4.7 | 3.38 | 1.39 | 1 | |
Enterprise value over EBITDA | -7.31 | -14.02 | -8.42 | -5.36 | -428.77 | |
EV to operating cash flow | -11.2 | -26.25 | -9.43 | -6.61 | 11.81 | |
EV to free cash flow | -10.8 | -25.9 | -9.28 | -6.47 | 12.07 | |
Earnings yield | -0.13 | -0.06 | -0.1 | -0.12 | -0.05 | |
Free cash flow yield | -0.09 | -0.04 | -0.1 | -0.13 | 0.06 | |
Debt to equity | 0.08 | 0.1 | 0.15 | 0.15 | 0.12 | |
Debt to assets | 0.04 | 0.04 | 0.08 | 0.08 | 0.06 | |
Net debt to EBITDA | 0.55 | 0.75 | 0.86 | 0.86 | 123.96 | |
Current ratio | 2.23 | 1.96 | 2.78 | 2.61 | 2.4 | |
Interest coverage | 36.95 | -279.63 | -492.24 | -6.21K | 0 | |
Income quality | 0.64 | 0.53 | 0.89 | 0.91 | -1.43 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.74 | 0.51 | 0.54 | 0.39 | 0.3 | |
Research and developement to revenue | 0.1 | 0.06 | 0.06 | 0.07 | 0.06 | |
Intangibles to total assets | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 | |
Capex to operating cash flow | 0.04 | 0.01 | 0.02 | 0.02 | -0.02 | |
Capex to revenue | -0.02 | 0 | -0.01 | 0 | 0 | |
Capex to depreciation | -0.49 | -0.09 | -0.25 | -0.18 | -0.09 | |
Stock based compensation to revenue | 0.15 | 0.12 | 0.09 | 0.08 | 0.06 | |
Graham number | 2.11 | 1.35 | 2.01 | 1.4 | 0.75 | |
ROIC | -1.28 | -0.93 | -0.62 | -0.44 | -0.06 | |
Return on tangible assets | -0.81 | -0.5 | -0.45 | -0.27 | -0.09 | |
Graham Net | 0.11 | 0.04 | 0.19 | 0.12 | 0.16 | |
Working capital | 18.46M | 15.74M | 31.29M | 28.7M | 28.91M | |
Tangible asset value | 19.13M | 15.34M | 30.87M | 28M | 27.95M | |
Net current asset value | 13.72M | 10.29M | 22.79M | 21.18M | 23.03M | |
Invested capital | 0.08 | 0.1 | 0.15 | 0.15 | 0.12 | |
Average receivables | 3.3M | 2.43M | 3.96M | 6.85M | 6.86M | |
Average payables | 9.59M | 9.54M | 9.93M | 10.05M | 9.96M | |
Average inventory | 9.89M | 11.61M | 12.64M | 14.14M | 14.6M | |
Days sales outstanding | 17.15 | 16.59 | 28.28 | 42.97 | 22.86 | |
Days payables outstanding | 171.21 | 143.74 | 146.55 | 120.77 | 113.9 | |
Days of inventory on hand | 205.16 | 177.8 | 191.24 | 183.13 | 161.68 | |
Receivables turnover | 21.28 | 22 | 12.91 | 8.49 | 15.97 | |
Payables turnover | 2.13 | 2.54 | 2.49 | 3.02 | 3.2 | |
Inventory turnover | 1.78 | 2.05 | 1.91 | 1.99 | 2.26 | |
ROE | -1.54 | -1.13 | -0.81 | -0.5 | -0.17 | |
Capex per share | -0.01 | 0 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.28 | 0.3 | 0.27 | 0.26 | 0.28 | |
Net income per share | 0.01 | -0.02 | -0.03 | -0.01 | 0 | |
Operating cash flow per share | 0 | 0.04 | 0.04 | 0.01 | 0.01 | |
Free cash flow per share | -0.01 | 0.04 | 0.04 | 0 | 0.01 | |
Cash per share | 0.27 | 0.31 | 0.35 | 0.35 | 0.36 | |
Book value per share | 0.39 | 0.37 | 0.36 | 0.36 | 0.38 | |
Tangible book value per share | 0.38 | 0.37 | 0.35 | 0.36 | 0.37 | |
Share holders equity per share | 0.39 | 0.37 | 0.36 | 0.36 | 0.38 | |
Interest debt per share | 0.06 | 0.06 | 0.05 | 0.05 | 0.04 | |
Market cap | 124.12M | 114.44M | 117.7M | 109.57M | 107.22M | |
Enterprise value | 108.13M | 95.36M | 95.38M | 86.74M | 83.17M | |
P/E ratio | 46.11 | -21.51 | -13.43 | -28.56 | 235.14 | |
Price to sales ratio | 5.91 | 5.07 | 5.79 | 5.62 | 5.06 | |
POCF ratio | -378.4 | 40.99 | 35.88 | 276.7 | 186.8 | |
PFCF ratio | -248.23 | 42.37 | 35.99 | 296.14 | 193.89 | |
P/B Ratio | 4.33 | 4.08 | 4.34 | 4.01 | 3.77 | |
PTB ratio | 4.33 | 4.08 | 4.34 | 4.01 | 3.77 | |
EV to sales | 5.15 | 4.23 | 4.69 | 4.45 | 3.92 | |
Enterprise value over EBITDA | -74.88 | -48.46 | -50.95 | -124.09 | 137.48 | |
EV to operating cash flow | -329.67 | 34.16 | 29.08 | 219.04 | 144.9 | |
EV to free cash flow | -216.26 | 35.31 | 29.17 | 234.44 | 150.41 | |
Earnings yield | 0.01 | -0.01 | -0.02 | -0.01 | 0 | |
Free cash flow yield | 0 | 0.02 | 0.03 | 0 | 0.01 | |
Debt to equity | 0.15 | 0.15 | 0.15 | 0.14 | 0.12 | |
Debt to assets | 0.08 | 0.08 | 0.07 | 0.07 | 0.06 | |
Net debt to EBITDA | 11.07 | 9.69 | 11.92 | 32.66 | -39.75 | |
Current ratio | 2.61 | 2.53 | 2.43 | 2.43 | 2.4 | |
Interest coverage | 72.2 | -29.82 | -18.53 | -6.1 | 0 | |
Income quality | 0.23 | -1.47 | -1.5 | -0.41 | 5.04 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.29 | 0.28 | 0.36 | 0.3 | 0.26 | |
Research and developement to revenue | 0.06 | 0.05 | 0.07 | 0.06 | 0.05 | |
Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Capex to operating cash flow | 0.52 | -0.03 | 0 | -0.07 | -0.04 | |
Capex to revenue | -0.01 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.38 | -0.21 | -0.02 | -0.06 | -0.06 | |
Stock based compensation to revenue | 0.06 | 0.06 | 0.07 | 0.06 | 0.05 | |
Graham number | 0.28 | 0.39 | 0.49 | 0.32 | 0.11 | |
ROIC | 0.02 | -0.04 | -0.07 | -0.03 | 0.01 | |
Return on tangible assets | 0.01 | -0.03 | -0.04 | -0.02 | 0 | |
Graham Net | 0.12 | 0.14 | 0.14 | 0.15 | 0.16 | |
Working capital | 28.7M | 28.14M | 27.32M | 27.74M | 28.91M | |
Tangible asset value | 28M | 27.39M | 26.56M | 26.76M | 27.95M | |
Net current asset value | 21.18M | 20.81M | 20.36M | 21.01M | 23.03M | |
Invested capital | 0.15 | 0.15 | 0.15 | 0.14 | 0.12 | |
Average receivables | 6.61M | 8.85M | 7.67M | 5.86M | 5.42M | |
Average payables | 9.4M | 9.32M | 9.49M | 9.61M | 9.72M | |
Average inventory | 15.16M | 13.29M | 11.94M | 12.3M | 13.57M | |
Days sales outstanding | 36.36 | 36.79 | 27.09 | 25.86 | 22.22 | |
Days payables outstanding | 97.01 | 89.13 | 113.32 | 109.99 | 111.5 | |
Days of inventory on hand | 147.1 | 118.58 | 135.25 | 150.96 | 158.28 | |
Receivables turnover | 2.48 | 2.45 | 3.32 | 3.48 | 4.05 | |
Payables turnover | 0.93 | 1.01 | 0.79 | 0.82 | 0.81 | |
Inventory turnover | 0.61 | 0.76 | 0.67 | 0.6 | 0.57 | |
ROE | 0.02 | -0.05 | -0.08 | -0.04 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CDXC Frequently Asked Questions
What is ChromaDex Corporation stock symbol ?
ChromaDex Corporation is a US stock , located in Los angeles of Ca and trading under the symbol CDXC
What is ChromaDex Corporation stock quote today ?
ChromaDex Corporation stock price is $3.48 today.
Is ChromaDex Corporation stock public?
Yes, ChromaDex Corporation is a publicly traded company.